Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 44

Sort by

Sort Order Select

Journal Articles

Real-world outcomes of FLAG-ida salvage therapy in relapsed/refractory AML and validation of the salflage score: A pethema registry study

Gaspar Aspas Requena, Rebeca Rodriguez-Veiga, Cristina Gil, Carmen Botella, Eliana Aguiar, Fernanda Trigo, Mercedes Colorado, Teresa Bernal Del Castillo, Eva Barragán, Mar Tormo, Eduardo Rodríguez-Arbolí, Josefina Serrano, Raimundo García-Boyero, Tamara Castaño, Pilar Herrera Puente, Monica Romero, Maria Jose Sayas Lloris, Lorenzo Algarra, Carlos Rodríguez-Medina, Claudia Sossa, Jorge Labrador, Susana Vives, María Luz Amigo, Olga Salamero, Marta Valero Núñez, Christine Rojas, Veronica Lizama, María García-Fortes, María-Belén Vidriales, Celina Benavente, Maria Dolores Madrigal, Marcela Espinoza, Manuel Pérez-Encinas, María Lourdes Amador Barciela, Guiomar Bautista Carrascosa, Antonio Solana-Altabella, Isabel Cano-Ferri, Rafael Colmenares, David Martinez-Cuadron, Stefan Wickenhauser, Juan Miguel Bergua Burgues, Pau Montesinos

Blood (2025) 146 (Supplement 1): 1619.

https://doi.org/10.1182/blood-2025-1619

Published: 2025

Journal Articles

Measurable residual disease (MRD) assessment as an early end point oftreatment efficacy in acute myeloid leukemia (AML): A pethema studyof 2,623 patients (Pts) treated with intensive therapy

Bruno Paiva, Leire Burgos, Carmen Gonzalez, Rebeca Rodriguez Veiga, Antonio Solana-Altabella, Pilar Lloret-Madrid, Evelyn Acuña-Cruz, Cristina Gil, Carmen Botella, Eduardo Rodríguez-Arbolí, Teresa Caballero, Teresa Bernal Del Castillo, Maria Teresa Cedena Romero, Pilar Herrera Puente, Claudia Sossa, Josefina Serrano, Joaquín Sánchez-García, José Luis López Lorenzo, María-Belén Vidriales, Mar Tormo, Monica Romero, Mercedes Colorado, Celina Benavente, Juan Miguel Bergua Burgues, Manuel Pérez-Encinas, Lorenzo Algarra, Carlos Rodríguez-Medina, Dolly Viviana Fiallo Suarez, Raimundo García-Boyero, Luis Felipe Casado Montero, Jorge Labrador, Manuel Barrios García, Beatriz De Rueda Ciller, Marcela Espinoza, Maria Jose Sayas Lloris, Diana Cuervo, María Luz Amigo, Jose-Mario Mariz, Karoll Giovanna Gomez Correcha, Carmen Couto, Esther Perez, Ágata Almela, Susana Vives, Esperanza Lavilla-Rubira, Olga Arce-Fernández, Maria Teresa Olave Rubio, Miguel Lopez, Maria Dolores Madrigal, Lara María Gómez García, Sofia Grille, Sebastián Hidalgo, Daniel García Belmonte, Maria Jose Garcia, Maria Del Carmen Martinez Chamorro, Olga Salamero, Amparo Sempere, Beatriz Martín Herreros, Armando Mena Duran, David Martinez-Cuadron, Pau Montesinos

Blood (2025) 146 (Supplement 1): 5293.

https://doi.org/10.1182/blood-2025-5293

Published: 2025

Journal Articles

Identifying patients with indolent Acute Myeloid Leukemia: Long term survivors after best supportive care only, results from the pethema registry

Jorge Labrador, David Martinez-Cuadron, Cristina Gil, Mar Tormo, Josefina Serrano, Pilar Martinez Sanchez, Eduardo Rodríguez-Arbolí, Jose-Mario Mariz, Fernanda Trigo, Teresa Bernal Del Castillo, Juan Miguel Bergua Burgues, Carlos Rodríguez-Medina, Olga Salamero, Joana Brioso Infante, Juan Manuel Alonso-Dominguez, Pilar Herrera Puente, María Luz Amigo, Susana Vives, Raimundo García-Boyero, Lorenzo Algarra, Mercedes Colorado, Monica Romero, Claudia Sossa, Maria Vidriales Vicente, Armando Mena Duran, Celina Benavente, Esperanza Lavilla-Rubira, Maria Jose Sayas Lloris, Emília Cortesão, Veronica Lizama, Olga Arce-Fernández, María García-Fortes, Maria Dolores Madrigal, Manuel Perez Encinas, Marta Valero-Nuñez, Luis Felipe Casado Montero, Maria Teresa Olave Rubio, Ágata Almela, Diana Cuervo, Victor Noriega Concepción, Marcela Espinoza, Beatriz De Rueda Ciller, Manuel Barrios García, Rosa Fernández, Bernardo González González, Carmen Montes, Christine Rojas, Esther Pérez-Santaolalla, María Lourdes Amador Barciela, ANA Yurena Oliva Hernandez, Rebeca Rodriguez-Veiga, Isabel Cano, Evelyn Acuña-Cruz, Antonio Solana-Altabella, Pau Montesinos

Blood (2025) 146 (Supplement 1): 875.

https://doi.org/10.1182/blood-2025-875

Published: 2025

Journal Articles

Clinical impact of FLT3 microclones on outcomes in patients with newly diagnosed FLT3-ITD negative AML: A subanalysis from the pethema quiwi trial

Blood (2025) 146 (Supplement 1): 1719.

https://doi.org/10.1182/blood-2025-1719

Published: 2025

Journal Articles

Impact of molecular profile and variant allele frequency in patients with Acute Myeloid Leukemia undergoing allogeneic transplantation in first remission: A study by the pethema group

Rafael Colmenares, Eva Barragán, Rebeca Rodriguez-Veiga, Laura Torres-Miñana, Joaquín Sánchez-García, Mar Tormo, Teresa Bernal Del Castillo, Pilar Martinez Sanchez, Eduardo Rodríguez-Arbolí, Cristina Gil, Elena Soria-Saldise, Josefina Serrano, Mercedes Colorado, María García-Fortes, Cristina Bilbao, José Luis López Lorenzo, Maria Jose Larrayoz, Esther Pérez-Santaolalla, Esperanza Lavilla-Rubira, Lorenzo Algarra, Maria Carmen García-Garay, Carmen Chillon, Melissa Torres-Ochando, Raimundo García-Boyero, Carmen Couto, Ágata Almela, Victor Noriega Concepción, Marta Callejas, Manuel Barrios García, Soledad Casado, Amaia Balerdi Malcorra, Ana Cabello, Jorge Labrador, María Carmen Mateos, María Luz Amigo, Manuel Pérez-Encinas, Maria Jose Garcia, Lisette Costilla-Barriga, Juan Miguel Bergua Burgues, Gonzalo Carreño, Joaquin Martinez-Lopez, Rosa Ayala Diaz, Pau Montesinos

Blood (2025) 146 (Supplement 1): 6998.

https://doi.org/10.1182/blood-2025-6998

Published: 2025

Journal Articles

Prognosis of FLT3 ligand level in newly diagnosed FLT3-ITD negative Acute Myeloid Leukemia patients enrolled in the pethema QUIWI trial

Blood (2025) 146 (Supplement 1): 1694.

https://doi.org/10.1182/blood-2025-1694

Published: 2025

Journal Articles

Improved outcomes in 17,908 acute myeloid leukemia patients across last three decades: Results from the multinational pethema registry

Blood (2025) 146 (Supplement 1): 40.

https://doi.org/10.1182/blood-2025-40

Published: 2025

Journal Articles

A Multicenter, Prospective, Non-Randomized, Phase I-II Trial to Asses the Efficacy and Safety of the Combination or Oral Quizartinib and the FLAG-IDA Chemotherapy Regimen in First Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

Blood (2024) 144 (Supplement 1): 2874.

https://doi.org/10.1182/blood-2024-200280

Published: 2024

Journal Articles

Engaging Innate Immunity By AFM28, an Innate Cell Engager (ICE®) Targeting CD123-Positive Leukemic Cells in Patients with Relapsed/Refractory Acute Myeloid Leukemia: Safety and Efficacy Results of a First-in-Human Phase 1 Study

Pau Montesinos, Montserrat Arnan, Stephane De Botton, Maria Calbacho, Rebeca Rodriguez Veiga, Pierre Bories, Belén Ansoleaga, Thomas Hueso, Naval Daver, Lydia Wunderle, Andreas Harstrick, Kerstin Pietzko, Pallavi Hajela, Alexandra Vasile, Tania Witte, Elmarie Saenger, Christian Récher

Blood (2024) 144 (Supplement 1): 738.

https://doi.org/10.1182/blood-2024-194356

Published: 2024

Journal Articles

Final Results of Quiwi: A Double Blinded, Randomized Pethema Trial Comparing Standard Chemotherapy Plus Quizartinib Versus Placebo in Adult Patients with Newly Diagnosed FLT3 -ITD Negative AML

Pau Montesinos, Rebeca Rodriguez-Veiga, Juan Miguel Bergua Burgues, Jesús Lorenzo Algarra, Carmen Botella, Eduardo Rodriguez Arboli, Teresa Bernal Del Castillo, Mar Tormo, Maria Calbacho, Olga Salamero, Josefina Serrano, Victor Noriega Concepcion, Juan Antonio Lopez Lopez, Susana Vives, Jose Luis Lopez Lorenzo, Mercedes Colorado, Maria Vidriales Vicente, Raimundo Garcia Boyero, Maria Teresa Olave Rubio, Pilar Herrera, Olga Arce, Manuel Barrios Garcia, Maria Jose Sayas Lloris, Marta Polo, Maria Isabel Gómez Roncero, Eva Barragán, Rosa Ayala, Carmen Chillon, Maria Jose Calasanz, Bruno Paiva, Blanca Boluda, Ignacio Casas Aviles, Pilar Lloret Madrid, María-José Sánchez-Sánchez, Carlos Rodríguez-Medina, Laida Cuevas Palomares, Jose Ángel Raposo Puglia, M Carmen Mateos Rodríguez, Matxalen Olivares Salaverri, Maria Del Carmen Martinez Chamorro, Natalia Alonso Vence, Sandra Suarez Ordoñez, Irene Sanchez Vadillo, María Solé-Rodríguez, Bernardo Javier González González, Antonio Martinez Frances, Rebeca Cuello, Alfonso Fernández Fernández, David Martinez-Cuadron, Jorge Labrador

Blood (2024) 144 (Supplement 1): 1512.

https://doi.org/10.1182/blood-2024-204779

Published: 2024

Journal Articles

A Cutting-Edge Bioinformatics Tool for Neoantigen Identification in Unpaired RNA-Seq Samples of AML

Blood (2024) 144 (Supplement 1): 4986.

https://doi.org/10.1182/blood-2024-201407

Published: 2024

Journal Articles

Correlation of ELN-Risk and Gene Mutations with Quizartinib Efficacy in Patients with FLT3 -ITD-Negative Newly Diagnosed Acute Myeloid Leukemia in the Phase 2 Quiwi Pethema Trial

David Martinez-Cuadron, Rebeca Rodriguez-Veiga, Juan Miguel Bergua Burgues, Jesús Lorenzo Algarra, Carmen Botella, Jose Antonio Pérez-Simón, Teresa Bernal Del Castillo, Mar Tormo, Maria Calbacho, Olga Salamero, Josefina Serrano, Victor Noriega Concepcion, Juan Antonio Lopez Lopez, Susana Vives, Jose Luis Lopez Lorenzo, Mercedes Colorado, Maria Vidriales Vicente, Raimundo Garcia Boyero, Maria Teresa Olave Rubio, Pilar Herrera, Olga Arce, Manuel Barrios Garcia, Maria Jose Sayas Lloris, Marta Polo, Maria Isabel Gómez Roncero, Eva Barragán, Rosa Ayala, Carmen Chillon, Maria Jose Calasanz, Bruno Paiva, Blanca Boluda, Ignacio Casas Aviles, Pilar Lloret Madrid, Claudia Sargas, María-José Sánchez-Sánchez, Carlos Rodríguez-Medina, Laida Cuevas Palomares, Júlia Morán Sánchez, M Carmen Mateos Rodríguez, Matxalen Olivares Salaverri, Maria Del Carmen Martinez Chamorro, Natalia Alonso Vence, Sandra Suarez Ordonez, Irene Sanchez Vadillo, María Solé-Rodríguez, Bernardo Javier González González, Antonio Martinez Frances, Rebeca Cuello, Alfonso Fernández Fernández, Jorge Labrador, Pau Montesinos

Blood (2024) 144 (Supplement 1): 2895.

https://doi.org/10.1182/blood-2024-205064

Published: 2024

Journal Articles

Enhanced Validation of the FLT3 -like Gene Expression Signature As a Predictive Biomarker for Quizartinib Response in FLT3-ITD Negative Acute Myeloid Leukemia: Expanded Cohort and Extended Follow-up from the Pethema Quiwi Trial

Blood (2024) 144 (Supplement 1): 1552.

https://doi.org/10.1182/blood-2024-201264

Published: 2024

Journal Articles

Treatment Approaches for Blastic Plasmacytoid Dendritic Cell Neoplasm: Data from the Pethema and PALG Epidemiologic Registry

Antonio Solana-Altabella, Irene Navarro Vicente, Marta Sobas, Josefina Serrano, Magdalena Karasek, Manuel Perez Encinas, Jorge Labrador, Cristina de la Fuente, Olga Salamero, Rafael Colmenares, Tamara Castaño, Lorenzo Algarra, María García-Fortes, Maria Dunia De Miguel, Fernanda Trigo, Delfim Duarte, Virginia Pradillo Fernandez, Maria Angeles Foncillas, Victor Noriega Concepción, Pedro Paúl Vidaller, Teresa Bernal Del Castillo, Juan Miguel Miguel Bergua Burgues, Gabriela Rodriguez Macias, Eduardo Rodriguez Arboli, Isabel Simon, Nerea Caminos, Ada Esteban-Figuerola, Joana Brioso Infante, Monica Alejandra Romero, Rolando Omar Vallansot, Lukasz Targonski, Emilia Ulenberg, Krzysztof Lewandowski, Anna Armatys, Renata Guzicka-Kazmierczak, Małgorzata Sobczyk-Kruszelnicka, Andrzej Szczepaniak, Beatriz De Rueda Ciller, Esperanza Lavilla-Rubira, Maria Paz Garrastazul Sánchez, Jackeline Solano Tovar, Cristina Insua Vilas, Maria Dolores Madrigal, Laura Lamarca Eraso, Mar Tormo, Carmen Botella, Mercedes Colorado, Manuel Barrios García, Rebeca Rodriguez-Veiga, Pilar Lloret Madrid, David Martinez Cuadron, Pau Montesinos

Blood (2024) 144 (Supplement 1): 320.

https://doi.org/10.1182/blood-2024-205106

Published: 2024

Journal Articles

Clinical Features and Outcomes in 228 Patients Diagnosed with Blastic Plasmocytoid Dendritic Cell Neoplasm: A Pethema/PALG Study

Irene Navarro Vicente, Antonio Solana-Altabella, Marta Sobas, Josefina Serrano, Magdalena Karasek, Manuel Perez Encinas, Jorge Labrador, Cristina de la Fuente, Olga Salamero, Rafael Colmenares Gil, Tamara Castaño, Jesús Lorenzo Algarra, María García-Fortes, Maria Dunia De Miguel, Fernanda Trigo, Delfim Duarte, Virginia Pradillo Fernandez, Maria Angeles Foncillas, Victor Noriega Concepcion, Pedro Paúl Vidaller, Teresa Bernal Del Castillo, Juan Miguel Bergua Burgues, Gabriela Rodriguez Macias, Eduardo Rodriguez Arboli, Isabel Simon, Nerea Caminos, Ada Esteban-Figuerola, Joana Brioso Infante, Monica Alejandra Romero, Rolando Omar Vallansot, Lukasz Targonski, Emilia Ulenberg, Krzysztof Lewandowski, Anna Armatys, Renata Guzicka-Kazmierczak, Małgorzata Sobczyk-Kruszelnicka, Andrzej Szczepaniak, Beatriz De Rueda Ciller, Esperanza Lavilla, Maria Paz Garrastazul Sánchez, Jackeline Solano Tovar, Cristina Insua Vilas, Maria Dolores Madrigal Toscano, Laura Lamarca, Mar Tormo, Cristina Gil, Mercedes Colorado, Manuel Barrios García, Matxalen Olivares Salaverri, Lisette Costilla-Barriga, Rebeca Rodriguez Veiga, Pilar Lloret Madrid, David Martinez Cuadron, Pau Montesinos

Blood (2024) 144 (Supplement 1): 319.

https://doi.org/10.1182/blood-2024-205172

Published: 2024

Journal Articles

Molecular Mechanisms of Quizartinib Response in FLT3-ITD Negative AML: An Updated Analysis from the Pethema Quiwi Trial

Blood (2024) 144 (Supplement 1): 6135.

https://doi.org/10.1182/blood-2024-201316

Published: 2024

Journal Articles

Exploring Potential Molecular Mechanisms of Drug Response in FLT3-ITD Negative AML Patients Treated with Quizartinib Vs Placebo Plus Standard Chemotherapy in the Quiwi Trial

Blood (2023) 142 (Supplement 1): 6037.

https://doi.org/10.1182/blood-2023-180710

Published: 2023

Journal Articles

The FLT3-like Gene Expression Signature Predicts Response to Quizartinib in Wild-Type FLT3 Acute Myeloid Leukemia: An Analysis of the Pethema Quiwi Trial

Blood (2023) 142 (Supplement 1): 974.

https://doi.org/10.1182/blood-2023-180482

Published: 2023

Journal Articles

Real-World Outcomes Using Front-Line Midostaurine in Combination with Intensive Chemotherapy for Patients Aged ≥ 60 Years Old with FLT3 Mutated Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 2864.

https://doi.org/10.1182/blood-2023-190128

Published: 2023

Journal Articles

A High Percentage of DNAM-1+ and Low Percentage of Tactile+ NK Cells at Diagnosis Correlate with Complete Response and Survival in AML: A Sub-Analysis of the Ven-a-Qui Pethema Trial

Blood (2023) 142 (Supplement 1): 2960.

https://doi.org/10.1182/blood-2023-189676

Published: 2023

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Real-world outcomes of FLAG-ida salvage therapy in relapsed/refractory AML and validation of the salflage score: A pethema registry study

Measurable residual disease (MRD) assessment as an early end point oftreatment efficacy in acute myeloid leukemia (AML): A pethema studyof 2,623 patients (Pts) treated with intensive therapy

Identifying patients with indolent Acute Myeloid Leukemia: Long term survivors after best supportive care only, results from the pethema registry

Clinical impact of FLT3 microclones on outcomes in patients with newly diagnosed FLT3-ITD negative AML: A subanalysis from the pethema quiwi trial

Impact of molecular profile and variant allele frequency in patients with Acute Myeloid Leukemia undergoing allogeneic transplantation in first remission: A study by the pethema group

Prognosis of FLT3 ligand level in newly diagnosed FLT3-ITD negative Acute Myeloid Leukemia patients enrolled in the pethema QUIWI trial

Improved outcomes in 17,908 acute myeloid leukemia patients across last three decades: Results from the multinational pethema registry

A Multicenter, Prospective, Non-Randomized, Phase I-II Trial to Asses the Efficacy and Safety of the Combination or Oral Quizartinib and the FLAG-IDA Chemotherapy Regimen in First Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

Engaging Innate Immunity By AFM28, an Innate Cell Engager (ICE®) Targeting CD123-Positive Leukemic Cells in Patients with Relapsed/Refractory Acute Myeloid Leukemia: Safety and Efficacy Results of a First-in-Human Phase 1 Study

Final Results of Quiwi: A Double Blinded, Randomized Pethema Trial Comparing Standard Chemotherapy Plus Quizartinib Versus Placebo in Adult Patients with Newly Diagnosed FLT3 -ITD Negative AML

A Cutting-Edge Bioinformatics Tool for Neoantigen Identification in Unpaired RNA-Seq Samples of AML

Correlation of ELN-Risk and Gene Mutations with Quizartinib Efficacy in Patients with FLT3 -ITD-Negative Newly Diagnosed Acute Myeloid Leukemia in the Phase 2 Quiwi Pethema Trial

Enhanced Validation of the FLT3 -like Gene Expression Signature As a Predictive Biomarker for Quizartinib Response in FLT3-ITD Negative Acute Myeloid Leukemia: Expanded Cohort and Extended Follow-up from the Pethema Quiwi Trial

Treatment Approaches for Blastic Plasmacytoid Dendritic Cell Neoplasm: Data from the Pethema and PALG Epidemiologic Registry

Clinical Features and Outcomes in 228 Patients Diagnosed with Blastic Plasmocytoid Dendritic Cell Neoplasm: A Pethema/PALG Study

Molecular Mechanisms of Quizartinib Response in FLT3-ITD Negative AML: An Updated Analysis from the Pethema Quiwi Trial

Exploring Potential Molecular Mechanisms of Drug Response in FLT3-ITD Negative AML Patients Treated with Quizartinib Vs Placebo Plus Standard Chemotherapy in the Quiwi Trial

The FLT3-like Gene Expression Signature Predicts Response to Quizartinib in Wild-Type FLT3 Acute Myeloid Leukemia: An Analysis of the Pethema Quiwi Trial

Real-World Outcomes Using Front-Line Midostaurine in Combination with Intensive Chemotherapy for Patients Aged ≥ 60 Years Old with FLT3 Mutated Acute Myeloid Leukemia

A High Percentage of DNAM-1+ and Low Percentage of Tactile+ NK Cells at Diagnosis Correlate with Complete Response and Survival in AML: A Sub-Analysis of the Ven-a-Qui Pethema Trial

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only